|
2010 Conference Publication Serum ferritin: An independent predictor of mortality in patients awaiting liver transplantation in a cohort and validation study of patients from Australia and North AmericaWalker, N. M., Stuart, K. A., Ryan, R. J., Desai, S., Saab, S., Nicol, J. A., Fletcher, L. M. and Crawford, D. H. G. (2010). Serum ferritin: An independent predictor of mortality in patients awaiting liver transplantation in a cohort and validation study of patients from Australia and North America. 45th Annual Meeting of the European-Association-for-the-Study-of-Liver, Vienna, Austria, April 14-18 2010. Amsterdam, Netherlands: Elsevier. doi: 10.1016/S0168-8278(10)60465-5 |
|
2010 Conference Publication HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatmentGeorge, J., Gane, E. J., Sievert, W. S., Desmond, P. A., Crawford, D., Roberts, S. K., Strasser, S. I., Heathcote, E. J., Marcellin, P., Sorbel, J. and Rousseau, F. (2010). HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment. unknown, unknown, unknown. MALDEN: WILEY-BLACKWELL PUBLISHING, INC. |
|
2010 Conference Publication Non-Svr to peginterferon Alfa-2a therapy and ribavirin is strongly predicted by baseline factors and week 8 on-treatment viral load in Hcv genotype (gt) 1 patients: New insights from cart analysis of the chariot studyRoberts, S. K., Ferenci, P., Yoshihara, M., Crawford, D. H., Sieverf, W., McCaughan, G. W., Cheng, W., Weltman, M., Rawlinson, W. D., McCloud, P. I., Rizkalla, B. and Dore, G. J. (2010). Non-Svr to peginterferon Alfa-2a therapy and ribavirin is strongly predicted by baseline factors and week 8 on-treatment viral load in Hcv genotype (gt) 1 patients: New insights from cart analysis of the chariot study. 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, United States, 29 Oct-2 Nov, 2010. MALDEN: WILEY-BLACKWELL. |
|
2010 Conference Publication Altered expression of iron-regualtory genes in an animal model of cholestasisSobbe, A. L., Bridle, K.R., Fletcher, L. and Crawford, D, H. G. (2010). Altered expression of iron-regualtory genes in an animal model of cholestasis. Australian Gastroenterology Week 2010, Gold Coast, QLD, Australia, 20-23 October 2010. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1746.2010.06450.x |
|
2010 Conference Publication Efficacy of tenofovir disoproxil fumarate treatment in patients with a suboptimal response to adefovir dipivoxilSievert, W., George, J., Strasser, S. I., Crawford, D., Heathcote, E. J., Marcellin, P., Elsome, A. M., Sorbel, J. and Rousseau, F. (2010). Efficacy of tenofovir disoproxil fumarate treatment in patients with a suboptimal response to adefovir dipivoxil. unknown, unknown, unknown. MALDEN: WILEY-BLACKWELL PUBLISHING, INC. |
|
2009 Conference Publication Efficacy and safety of peginterferon alfa-2A 360 mu g/week in combination with ribavirin in hepatitis C genotype 1 patients with cirrhosis : Analysis from the chariot studyCheng, W. S. C., Roberts, S., Weltman, M., Crawford, D. H. G., Sievert, W., McCaughan, G., Rawlinson, W., Desmond, P., Yoshihara, M., Rizkalla, B., DePamphilis, J., Marks, P. and Dore, G. J. (2009). Efficacy and safety of peginterferon alfa-2A 360 mu g/week in combination with ribavirin in hepatitis C genotype 1 patients with cirrhosis : Analysis from the chariot study. 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Copenhagen, Denmark, 22-26 April 2009. Copenhagan, Denmark: Elsevier. doi: 10.1016/S0168-8278(09)60603-6 |
|
2009 Conference Publication High-dose peginterferon alfa-2A (40KD) induction therapy and standard ribavirin enhances early but not sustained virological responses in HCV genotype 1 patients: Final chariot study resultsRoberts, S., Weltman, M., Crawford, D. H. G., Cheng, W. S. C., Sievert, W., McCaughan, G., Desmond, P., Rawlinson, W., Marks, P., Yoshihara, M., Rizkalla, B., DePamphilis, J. and Dore, G. J. (2009). High-dose peginterferon alfa-2A (40KD) induction therapy and standard ribavirin enhances early but not sustained virological responses in HCV genotype 1 patients: Final chariot study results. 44th Annual Meeting of the European Association for the Study of the Liver, Copenhagen, Denmark, 22-26 April 2009. AMSTERDAM: ELSEVIER SCIENCE BV. doi: 10.1016/S0168-8278(09)60126-4 |
|
2009 Conference Publication The antifibrotic effect of low dose rapamycin is diminished in Mdr2-/- when administered to animals with advanced hepatic fibrosisSobbe, AL, Bridle, KR and Crawford, DHG (2009). The antifibrotic effect of low dose rapamycin is diminished in Mdr2-/- when administered to animals with advanced hepatic fibrosis. Australia & New Zealand Medical & Surgical Gastrointestinal Week 2009, Sydney, Australia, 21-24 October 2009. MALDEN: WILEY-BLACKWELL PUBLISHING, INC. |
|
2009 Conference Publication PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIESMarcellin, P, Jensen, DM, Roberts, SK, Hadziyannis, SJ, Dore, GJ, Diago, M, Weltman, M, McCaughan, GW, Cheng, W, Crawford, DH, Sievert, W, Rawlinson, W, Solsky, J, Tietz, A and Rizzetto, M (2009). PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIES. 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston MA, OCT 30-NOV 03, 2009. HOBOKEN: JOHN WILEY & SONS INC. |
|
2009 Conference Publication SIGNIFICANT HEMOGLOBIN (HB) DECLINE DURING PEGYLATED INTERFERON AND RIBAVIRIN THERAPY IN HCV GENOTYPE 1 IS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR): AN ANALYSIS FROM THE CHARIOT STUDYSievert, W, Dore, GJ, McCaughan, GW, Yoshihara, M, Crawford, DH, Cheng, W, Weltman, M, Rawlinson, W, Rizkalla, B, McCloud, PI and Roberts, SK (2009). SIGNIFICANT HEMOGLOBIN (HB) DECLINE DURING PEGYLATED INTERFERON AND RIBAVIRIN THERAPY IN HCV GENOTYPE 1 IS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR): AN ANALYSIS FROM THE CHARIOT STUDY. 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston MA, OCT 30-NOV 03, 2009. HOBOKEN: JOHN WILEY & SONS INC. |
|
2009 Conference Publication Alcohol withdrawal is associated with a rebound increase in hepcidin expression: further evidence for an alcohol/hepcidin interactionTan, T. C. H., Heritage, M., Jaskowski, L. A., Murphy, T. L., Crawford, D. H. G. and Fletcher, L. M. (2009). Alcohol withdrawal is associated with a rebound increase in hepcidin expression: further evidence for an alcohol/hepcidin interaction. Australia & New Zealand Medical & Surgical Gastrointestinal Week 2009, Sydney, NSW, Australia, 21-24 October 2009. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1746.2009.06055.x |
|
2009 Conference Publication Baseline and ontreatment predictors of svr to peginterferon alfa-2a therapy and ribavirin in hcv genotype (GT) 1 treatment naive patients: New insights from the chariot studyWeltman, M, Dore, GJ, Sievert, W, McCaughan, GW, Crawford, DH, Cheng, W, Rawlinson, W, Yashihara, M, McCloud, PI, Rizkalla, B and Roberts, SK (2009). Baseline and ontreatment predictors of svr to peginterferon alfa-2a therapy and ribavirin in hcv genotype (GT) 1 treatment naive patients: New insights from the chariot study. 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston MA, OCT 30-NOV 03, 2009. HOBOKEN: JOHN WILEY & SONS INC. |
|
2009 Conference Publication Impact of low-level hepatitis C viraemia at week 24 on HCV treatment response in genotype 1 patientsBaleriola, C., Rawlinson, W., Chaverot, S., Stelzer-Braid, S., Yoshihara, M., Rizkalla, B., Dubois, D., Sievert, W., McCaughan, G., Crawford, D. H. G., Weltman, M., Cheng, W. S. C., Dore, G. J. and Roberts, S. (2009). Impact of low-level hepatitis C viraemia at week 24 on HCV treatment response in genotype 1 patients. 44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Copenhagen, Denmark, 22-26 April 2009. Copenhagan, Denmark: Elsevier. doi: 10.1016/S0168-8278(09)60600-0 |
|
2009 Conference Publication Advanced fibrosis in genotype 1 HCV infected patients receiving antiviral therapy is associated with virologic relapse independent of rapid (RVR) and early (EVR) virologic responseMcCaughan, G. W., Roberts, S. K., Weltman, M., Crawford, D. H., Sievert, W., Cheng, W., Rawlinson, W., Yoshihara, M., McCloud, P. I., Rizkalla, B. and Dore, G. J. (2009). Advanced fibrosis in genotype 1 HCV infected patients receiving antiviral therapy is associated with virologic relapse independent of rapid (RVR) and early (EVR) virologic response. 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, U.S.A., 30 October - 3 November 2009. HOBOKEN: JOHN WILEY & SONS INC. doi: 10.1002/hep.23307 |
|
2009 Conference Publication Expression of fibrogenic genes does not differentiate patients with rapid and non-rapid progression post liver transplant for hepatitis CSobbe, A.L., Bridle, K.R., Morgan, M.L., Lipka, G., Fletcher, L. and Crawford, D.H.G. (2009). Expression of fibrogenic genes does not differentiate patients with rapid and non-rapid progression post liver transplant for hepatitis C. Australia & New Zealand Medical & Surgical Gastrointestinal Week 2009, Sydney Convention & Exhibition Centre, Sydney, NSW, Australia, 21-24 October 2009. Carlton South, Vic.: Blackwell Publishing Asia. |
|
2009 Conference Publication Reimbursement policies in Asia-Pacific for chronic Hepatitis BLim, Seng Gee, Amarapurkar, Deepak N., Chan, Henry Lik-Yuen, Crawford, Darrell H., Gane, Edward J, Han, Kwang-Hyub, Ishaque, Shamsuddin M., Jafri, Syed M., Jia, Jidong, Kao, Jia-Horng, Lesmana, Laurentius A., Mizokami, Masashi, Mohamed, Rosmawati, Pham, Pham Hoang, Piratvisuth, Teerha, Sarin, Shiv K., Sollarno, Jose D., Yokosuka, Osamu and Lok, Anna S. (2009). Reimbursement policies in Asia-Pacific for chronic Hepatitis B. 60th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, U.S.A., 30 October - 3 November 2009. Hoboken, NJ, U.S.A.: John Wiley & Sons. doi: 10.1002/hep.23303 |
|
2008 Conference Publication Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosisCrawford, D. H. G., Murphy, T. L., Ramm, L. E., Fletcher, L. M., Clouston, A. D., Anderson, G. J., Subramaniam, V. N., Powell, L. W. and Ramm, G. A. (2008). Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. AGW 2008: Australian Gastroenterology Week 08, Brisbane, QLD, Australia, 22-25 October 2008. MALDEN: WILEY-BLACKWELL PUBLISHING, INC. doi: 10.1111/j.1440-1746.2008.05613.x |
|
2008 Conference Publication Hepcidin regulation in wild-type and HFE-/mice in response to alcohol consumption: Evidence for an alcohol-induced hypoxic responseFletcher, L. M., Heritage, M. L., Murphy, T. L., Bridle, K. R., Anderson, G. J. and Crawford, D. H. (2008). Hepcidin regulation in wild-type and HFE-/mice in response to alcohol consumption: Evidence for an alcohol-induced hypoxic response. 43rd Annual Meeting of the European Association for the Study of the Liver, Milan, Italy, 23-27 April, 2008. Copenhagen, Denmark: Elsevier. doi: 10.1016/S0168-8278(08)60888-0 |
|
2008 Conference Publication Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosisCrawford, Darrell H., Murphy, Therese L., Ramm, Louise E., Fletcher, Linda M., Clouston, Andrew D., Anderson, Gregory J., Subramaniam, V. Nathan, Powell, Lawrie W. and Ramm, Grant A. (2008). Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. The Liver Meeting 2008: 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, U.S.A., 31 October-4 November 2008. Hoboken, NJ, U.S.A.: John Wiley & Sons. doi: 10.1002/hep.22641 |
|
2008 Conference Publication Obesity is linked with increased clot strength and impaired fibrinolysis in nonalcoholic fatty liver diseaseHickman, I. J., Sullivan, C. M., Flight, S., Campbell, C., Crawford, D. H., Masci, P. P., O'Moore-Sullivan, T. M., Prins, J. B. and Macdonald, G. A. (2008). Obesity is linked with increased clot strength and impaired fibrinolysis in nonalcoholic fatty liver disease. 16th European Congress on Obesity, Geneva, Switzerland, 14-17 May 2008. LONDON: NATURE PUBLISHING GROUP. |
